Topic Review
Gastric Pentadecapeptide BPC 157 in Brain–Gut Axis/Gut–Brain Axis
BPC 157 therapy by rapidly activated collateral pathways counteracted the vascular and multiorgan failure concomitant to major vessel occlusion and, similar to noxious procedures, reversed initiated multicausal noxious circuit of the occlusion/occlusion-like syndrome. Severe intracranial (superior sagittal sinus) hypertension, portal and caval hypertensions, and aortal hypotension were attenuated/eliminated. Counteracted were the severe lesions in the brain, lungs, liver, kidney, and gastrointestinal tract. In particular, progressing thrombosis, both peripherally and centrally, and heart arrhythmias and infarction that would consistently occur were fully counteracted and/or almost annihilated.
  • 340
  • 26 Jul 2023
Topic Review
Gels for Neuropathic Pain
Neuropathic pain is a complex and debilitating condition that affects millions of people worldwide. Gels have emerged as a promising option for the treatment of neuropathic pain. Inclusion of various nanocarriers, such as cubosomes and niosomes, into gels results in pharmaceutical forms with higher drug stability and increased drug penetration into tissues compared to products currently marketed for the treatment of neuropathic pain.
  • 291
  • 28 Jul 2023
Topic Review
Gender Differences and NPS
Sex and gender deeply affect the subjective effects and the pharmaco-toxicological responses to drugs. Men are more likely than women to use almost all types of illicit drugs and to present to emergency departments for serious or fatal intoxications. However, women are just as likely as men to develop substance use disorders, and may be more susceptible to craving and relapse.
  • 787
  • 26 Oct 2020
Topic Review
Gender-Specific Pharmacokinetics and Pharmacodynamics
Women and men respond differently to treatments; this mainly depends on physiological, anatomical, and hormonal characteristics. The existence of the differences in therapeutic agent pharmacokinetics and pharmacodynamics influences the response to treatments.
  • 376
  • 30 May 2023
Topic Review
GenisteinSupplementation, CardiacFunction in Postmenopausal-Women with MetabolicSyndrome: Results from Pilot-Strain-Echo Study
Genistein, a soy-derived isoflavone, may improve cardiovascular risk profile in postmenopausal women with metabolic syndrome (MetS), but few literature data on its cardiac effects in humans are available. The aim of this sub-study of a randomized double-blind case-control study was to analyze the effect on cardiac function of one-year genistein dietary supplementation in 22 post-menopausal patients with MetS. Participants received 54 mg/day of genistein (n = 11) or placebo (n = 11) in combination with a Mediterranean-style diet and regular exercise. Left ventricular (LV) systolic function was assessed as the primary endpoint, according to conventional and strain-echocardiography measurements. Also, left atrial (LA) morphofunctional indices were investigated at baseline and at the final visit. Results were expressed as median with interquartile range (IQ). A significant improvement of LV ejection fraction (20.3 (IQ 12.5) vs. -1.67 (IQ 24.8); p = 0.040)), and LA area fractional change (11.1 (IQ 22.6) vs. 2.8 (9.5); p = 0.034)) were observed in genistein patients compared to the controls, following 12 months of treatment. In addition, body surface area indexed LA systolic volume and peak LA longitudinal strain significantly changed from basal to the end of the study in genistein-treated patients. One-year supplementation with 54 mg/day of pure genistein improved both LV ejection fraction and LA remodeling and function in postmenopausal women with MetS.
  • 576
  • 01 Nov 2020
Topic Review
Ginseng against Respiratory Tract Infections
Ginseng has been reported to inhibit bacterial pathways, thereby killing bacteria indirectly. It has also been shown to protect the host from bacterial invasion.
  • 1.0K
  • 30 Sep 2021
Topic Review
Glucagon and Its Receptors in the Mammalian Heart
Glucagon exerts effects on the mammalian heart. These effects include alterations in the force of contraction, beating rate, and changes in the cardiac conduction system axis. The cardiac effects of glucagon vary according to species, region, age, and concomitant disease. Depending on the species and region studied, the contractile effects of glucagon can be robust, modest, or even absent. Glucagon is detected in the mammalian heart and might act with an autocrine or paracrine effect on the cardiac glucagon receptors. The glucagon levels in the blood and glucagon receptor levels in the heart can change with disease or simultaneous drug application. 
  • 164
  • 06 Sep 2023
Topic Review
Glucosamine and Chondroitin for Osteoarthritis
Glucosamine is a water-soluble amino monosaccharide available in two forms (glucosamine sulphate and glucosamine hydrochloride), which is a normal constituent of glycosaminoglycans (GAGs) in cartilage matrix and in the synovial fluid and consequently present in high quantities in articular cartilage. It is a constituent of keratan sulphate. Chondroitin is a major component of the extracellular matrix of articular cartilage, which played an important role in creating considerable osmotic pressure. In this way, it could provide cartilage with resistance and elasticity to resist tensile stresses during loading conditions.
  • 406
  • 31 Dec 2021
Topic Review
Glutamate and GABA Dysfunction in Depression
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD.
  • 335
  • 15 Nov 2023
Topic Review
Glutamatergic System in Depression
Major depressive disorder (MDD) is a heterogeneous neuropsychological disorder characterized by a combination of symptoms that negatively impact the productivity and well-being of inflicted patients, including impairments in cognition, emotional regulation, memory, motor function, motivation, and possible suicidal ideation. Glutamate is the major excitatory neurotransmitter in the central nervous system. It plays an important role in several physiological functions.
  • 2.6K
  • 11 May 2022
  • Page
  • of
  • 106
Video Production Service